Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Natalia StarodubtsevaV.I. Kulakov National Medical Research Center for Obstetrics Gynecology and Perinatology, Ministry of Healthcare of Russian Federation, Oparina Str. 4, 117997 Moscow, Russia.ORCID 0000-0001-6650-5915
Alisa TokarevaV.I. Kulakov National Medical Research Center for Obstetrics Gynecology and Perinatology, Ministry of Healthcare of Russian Federation, Oparina Str. 4, 117997 Moscow, Russia.
Natalia FrankevichV.I. Kulakov National Medical Research Center for Obstetrics Gynecology and Perinatology, Ministry of Healthcare of Russian Federation, Oparina Str. 4, 117997 Moscow, Russia.
Alexey KononikhinV.I. Kulakov National Medical Research Center for Obstetrics Gynecology and Perinatology, Ministry of Healthcare of Russian Federation, Oparina Str. 4, 117997 Moscow, Russia.
Anna BugrovaV.I. Kulakov National Medical Research Center for Obstetrics Gynecology and Perinatology, Ministry of Healthcare of Russian Federation, Oparina Str. 4, 117997 Moscow, Russia.ORCID 0000-0003-1515-9447
Maria IndeykinaThe Center for Bio- and Medical Technologies, 121205 Moscow, Russia.ORCID 0000-0002-8177-7449
Evgenii KukaevV.I. Kulakov National Medical Research Center for Obstetrics Gynecology and Perinatology, Ministry of Healthcare of Russian Federation, Oparina Str. 4, 117997 Moscow, Russia.ORCID 0000-0002-8397-3574
Anna DerenkoV.I. Kulakov National Medical Research Center for Obstetrics Gynecology and Perinatology, Ministry of Healthcare of Russian Federation, Oparina Str. 4, 117997 Moscow, Russia.
Vladimir FrankevichV.I. Kulakov National Medical Research Center for Obstetrics Gynecology and Perinatology, Ministry of Healthcare of Russian Federation, Oparina Str. 4, 117997 Moscow, Russia.
Evgeny NikolaevThe Center for Bio- and Medical Technologies, 121205 Moscow, Russia.
Gennady SukhikhV.I. Kulakov National Medical Research Center for Obstetrics Gynecology and Perinatology, Ministry of Healthcare of Russian Federation, Oparina Str. 4, 117997 Moscow, Russia.
Funding
Russian Science Foundation 24-64-000006
6 · The paper itself
Abstract
This prospective study evaluated first-trimester markers in pregnancies with isolated and combined forms of fetal growth disorders and gestational diabetes mellitus (GDM). Among 1869 screened women, the analysis included 83 controls, 55 GDM, 22 isolated intrauterine growth restriction (iIUGR), and 33 isolated large-for-gestational-age (iLGA) cases, with GDM subgroups stratified by fetal growth (GDM with normal fetal weight, GDM + IUGR, and GDM + LGA). First-trimester clinical and routine biochemical parameters were recorded, and serum concentrations of 80 proteins were measured using targeted LC-MRM-MS proteomics. Different trajectories emerged: IUGR phenotypes showed low PAPP-A/PlGF and high TSH (
Indexed as
Diabetes, GestationalFetal Growth RetardationPregnancy Trimester, FirstAdultBiomarkersCase-Control StudiesFemaleFetal MacrosomiaHumansInfant, Large for Gestational AgePregnancyProspective StudiesProteomicsBiomarkersbiomarkerscomplement systemfetal macrosomiagestational diabetes mellitusintrauterine growth restrictionplacental dysfunctionpregnancyproteomics
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Integrated Clinical and Molecular Profiling of Fetal Growth Disorders in the First Trimester. · full record | Socratic